Yayın: Pharmacokinetics and bioavailability of danofloxacin in chukar partridge (Alectoris chukar) following intravenous, intramuscular, subcutaneous, and oral administrations
| dc.contributor.author | Corum, Orhan | |
| dc.contributor.author | Durna Corum, Duygu | |
| dc.contributor.author | Atik, Orkun | |
| dc.contributor.author | Eser Faki, Hatice | |
| dc.contributor.author | Altan, Feray | |
| dc.contributor.author | Uney, Kamil | |
| dc.date.accessioned | 2026-01-04T12:25:46Z | |
| dc.date.issued | 2018-11-25 | |
| dc.description.abstract | AbstractThe aim of the present study was to determine the pharmacokinetics (PKs) and bioavailability of danofloxacin in chukar partridge (Alectoris chukar) following intravenous (IV), intramuscular (IM), subcutaneous (SC), and oral (PO) administrations at a dose of 10 mg/kg. A total of eight clinically healthy chukar partridges weighing 480 ± 45 g were used for the investigation. The study was performed in a crossover design (2 × 2 × 2 × 2) with a 15‐day washout period between two administrations in four periods. The plasma concentrations of danofloxacin were determined using reversed‐phase high‐performance liquid chromatography. Noncompartmental PK parameters were also estimated. No local or systemic adverse drug effects were observed in any of the chukar partridges. The mean elimination half‐life ranged between 8.18 and 12.08 hr and differed statistically among administration routes. The mean peak plasma concentrations of danofloxacin following IM, SC, and PO administrations were 8.05, 9.58, and 3.39 μg/ml at 0.5, 1, and 4 hr, respectively. Following IM, SC, and PO administrations, the mean bioavailability was 86.33%, 134.40%, and 47.62%, respectively. The mean total clearance and volume of distribution at steady‐state following IV administration were 0.13 L hr−1 kg−1 and 0.96 L/kg, respectively. These data, including favorable PKs and the absence of adverse drug effects, suggest that danofloxacin is a useful antibiotic in chukar partridges. | |
| dc.description.uri | https://doi.org/10.1111/jvp.12737 | |
| dc.description.uri | https://pubmed.ncbi.nlm.nih.gov/30474236 | |
| dc.description.uri | https://dx.doi.org/10.1111/jvp.12737 | |
| dc.description.uri | https://avesis.deu.edu.tr/publication/details/3b8b0421-a50f-42f9-8be6-291febcdaa8a/oai | |
| dc.description.uri | https://avesis.deu.edu.tr/publication/details/29a63cf4-db67-4618-b1b0-678b71f402f0/oai | |
| dc.description.uri | https://hdl.handle.net/11468/17716 | |
| dc.description.uri | https://hdl.handle.net/20.500.12395/38080 | |
| dc.identifier.doi | 10.1111/jvp.12737 | |
| dc.identifier.eissn | 1365-2885 | |
| dc.identifier.endpage | 213 | |
| dc.identifier.issn | 0140-7783 | |
| dc.identifier.openaire | doi_dedup___::4972bd5dfb040f23893e388ba5b5461e | |
| dc.identifier.orcid | 0000-0003-3168-2510 | |
| dc.identifier.orcid | 0000-0003-1567-991x | |
| dc.identifier.orcid | 0000-0003-2411-7492 | |
| dc.identifier.orcid | 0000-0002-9017-763x | |
| dc.identifier.orcid | 0000-0002-8674-4873 | |
| dc.identifier.pubmed | 30474236 | |
| dc.identifier.scopus | 2-s2.0-85057225795 | |
| dc.identifier.startpage | 207 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12597/37040 | |
| dc.identifier.volume | 42 | |
| dc.identifier.wos | 000460077600009 | |
| dc.language.iso | eng | |
| dc.publisher | Wiley | |
| dc.relation.ispartof | Journal of Veterinary Pharmacology and Therapeutics | |
| dc.rights | OPEN | |
| dc.subject | Bioavailability | |
| dc.subject | Injections, Subcutaneous | |
| dc.subject | chukar partridge | |
| dc.subject | Administration, Oral | |
| dc.subject | Biological Availability | |
| dc.subject | Chukar Partridge | |
| dc.subject | Danofloxacin | |
| dc.subject | Injections, Intramuscular | |
| dc.subject | Anti-Bacterial Agents | |
| dc.subject | Injections, Intravenous | |
| dc.subject | danofloxacin | |
| dc.subject | Animals | |
| dc.subject | Pharmacokinetics | |
| dc.subject | Galliformes | |
| dc.subject | bioavailability | |
| dc.subject | pharmacokinetics | |
| dc.subject | Chromatography, High Pressure Liquid | |
| dc.subject | Fluoroquinolones | |
| dc.subject | Half-Life | |
| dc.subject.sdg | 3. Good health | |
| dc.title | Pharmacokinetics and bioavailability of danofloxacin in chukar partridge (Alectoris chukar) following intravenous, intramuscular, subcutaneous, and oral administrations | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.api.response | {"authors":[{"fullName":"Orhan Corum","name":"Orhan","surname":"Corum","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0003-3168-2510"},"provenance":null}},{"fullName":"Duygu Durna Corum","name":"Duygu","surname":"Durna Corum","rank":2,"pid":{"id":{"scheme":"orcid","value":"0000-0003-1567-991x"},"provenance":null}},{"fullName":"Orkun Atik","name":"Orkun","surname":"Atik","rank":3,"pid":{"id":{"scheme":"orcid","value":"0000-0003-2411-7492"},"provenance":null}},{"fullName":"Hatice Eser Faki","name":"Hatice","surname":"Eser Faki","rank":4,"pid":null},{"fullName":"Feray Altan","name":"Feray","surname":"Altan","rank":5,"pid":{"id":{"scheme":"orcid","value":"0000-0002-9017-763x"},"provenance":null}},{"fullName":"Kamil Uney","name":"Kamil","surname":"Uney","rank":6,"pid":{"id":{"scheme":"orcid","value":"0000-0002-8674-4873"},"provenance":null}}],"openAccessColor":null,"publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Bioavailability"},"provenance":null},{"subject":{"scheme":"keyword","value":"Injections, Subcutaneous"},"provenance":null},{"subject":{"scheme":"keyword","value":"chukar partridge"},"provenance":null},{"subject":{"scheme":"FOS","value":"0402 animal and dairy science"},"provenance":null},{"subject":{"scheme":"keyword","value":"Administration, Oral"},"provenance":null},{"subject":{"scheme":"keyword","value":"Biological Availability"},"provenance":null},{"subject":{"scheme":"FOS","value":"04 agricultural and veterinary sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Chukar Partridge"},"provenance":null},{"subject":{"scheme":"keyword","value":"Danofloxacin"},"provenance":null},{"subject":{"scheme":"keyword","value":"Injections, Intramuscular"},"provenance":null},{"subject":{"scheme":"keyword","value":"Anti-Bacterial Agents"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null},{"subject":{"scheme":"FOS","value":"0403 veterinary science"},"provenance":null},{"subject":{"scheme":"keyword","value":"Injections, Intravenous"},"provenance":null},{"subject":{"scheme":"keyword","value":"danofloxacin"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals"},"provenance":null},{"subject":{"scheme":"keyword","value":"Pharmacokinetics"},"provenance":null},{"subject":{"scheme":"keyword","value":"Galliformes"},"provenance":null},{"subject":{"scheme":"keyword","value":"bioavailability"},"provenance":null},{"subject":{"scheme":"keyword","value":"pharmacokinetics"},"provenance":null},{"subject":{"scheme":"keyword","value":"Chromatography, High Pressure Liquid"},"provenance":null},{"subject":{"scheme":"keyword","value":"Fluoroquinolones"},"provenance":null},{"subject":{"scheme":"keyword","value":"Half-Life"},"provenance":null}],"mainTitle":"Pharmacokinetics and bioavailability of danofloxacin in chukar partridge (<i>Alectoris chukar</i>) following intravenous, intramuscular, subcutaneous, and oral administrations","subTitle":null,"descriptions":["<jats:title>Abstract</jats:title><jats:p>The aim of the present study was to determine the pharmacokinetics (<jats:styled-content style=\"fixed-case\">PK</jats:styled-content>s) and bioavailability of danofloxacin in chukar partridge (<jats:italic>Alectoris chukar</jats:italic>) following intravenous (<jats:styled-content style=\"fixed-case\">IV</jats:styled-content>), intramuscular (<jats:styled-content style=\"fixed-case\">IM</jats:styled-content>), subcutaneous (<jats:styled-content style=\"fixed-case\">SC</jats:styled-content>), and oral (<jats:styled-content style=\"fixed-case\">PO</jats:styled-content>) administrations at a dose of 10 mg/kg. A total of eight clinically healthy chukar partridges weighing 480 ± 45 g were used for the investigation. The study was performed in a crossover design (2 × 2 × 2 × 2) with a 15‐day washout period between two administrations in four periods. The plasma concentrations of danofloxacin were determined using reversed‐phase high‐performance liquid chromatography. Noncompartmental <jats:styled-content style=\"fixed-case\">PK</jats:styled-content> parameters were also estimated. No local or systemic adverse drug effects were observed in any of the chukar partridges. The mean elimination half‐life ranged between 8.18 and 12.08 hr and differed statistically among administration routes. The mean peak plasma concentrations of danofloxacin following <jats:styled-content style=\"fixed-case\">IM</jats:styled-content>,<jats:styled-content style=\"fixed-case\"> SC</jats:styled-content>, and <jats:styled-content style=\"fixed-case\">PO</jats:styled-content> administrations were 8.05, 9.58, and 3.39 μg/<jats:styled-content style=\"fixed-case\">ml</jats:styled-content> at 0.5, 1, and 4 hr, respectively. Following <jats:styled-content style=\"fixed-case\">IM</jats:styled-content>,<jats:styled-content style=\"fixed-case\"> SC</jats:styled-content>, and <jats:styled-content style=\"fixed-case\">PO</jats:styled-content> administrations, the mean bioavailability was 86.33%, 134.40%, and 47.62%, respectively. The mean total clearance and volume of distribution at steady‐state following <jats:styled-content style=\"fixed-case\">IV</jats:styled-content> administration were 0.13 L hr<jats:sup>−1</jats:sup> kg<jats:sup>−1</jats:sup> and 0.96 L/kg, respectively. These data, including favorable <jats:styled-content style=\"fixed-case\">PK</jats:styled-content>s and the absence of adverse drug effects, suggest that danofloxacin is a useful antibiotic in chukar partridges.</jats:p>"],"publicationDate":"2018-11-25","publisher":"Wiley","embargoEndDate":null,"sources":["Crossref"],"formats":["application/pdf"],"contributors":["Selcuk University Institutional Repository"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Journal of Veterinary Pharmacology and Therapeutics","issnPrinted":"0140-7783","issnOnline":"1365-2885","issnLinking":null,"ep":"213","iss":null,"sp":"207","vol":"42","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::4972bd5dfb040f23893e388ba5b5461e","originalIds":["10.1111/jvp.12737","50|doiboost____|4972bd5dfb040f23893e388ba5b5461e","30474236","2903035093","50|od______2605::5580aab1a39c7ec5da7845864e3168d3","3b8b0421-a50f-42f9-8be6-291febcdaa8a","50|od______2605::bbcf1fe766ed4e6d595f1e9a6a1f9e47","29a63cf4-db67-4618-b1b0-678b71f402f0","50|od______3346::2051dcd45d607f1b6218635a048c208d","oai:acikerisim.dicle.edu.tr:11468/17716","oai:acikerisim.selcuk.edu.tr:20.500.12395/38080","50|od______4883::6cc1bf95c97c31a5f42a4e85afb34aa9"],"pids":[{"scheme":"doi","value":"10.1111/jvp.12737"},{"scheme":"pmid","value":"30474236"},{"scheme":"handle","value":"11468/17716"},{"scheme":"handle","value":"20.500.12395/38080"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":17,"influence":3.1980298e-9,"popularity":1.2426179e-8,"impulse":7,"citationClass":"C4","influenceClass":"C5","impulseClass":"C4","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1111/jvp.12737"}],"license":"Wiley Online Library User Agreement","type":"Article","urls":["https://doi.org/10.1111/jvp.12737"],"publicationDate":"2018-11-25","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"30474236"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12737"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/30474236"],"publicationDate":"2019-03-25","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12737"},{"scheme":"mag_id","value":"2903035093"}],"type":"Article","urls":["https://dx.doi.org/10.1111/jvp.12737"],"refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12737"}],"type":"Article","urls":["https://avesis.deu.edu.tr/publication/details/3b8b0421-a50f-42f9-8be6-291febcdaa8a/oai"],"publicationDate":"2019-03-01","refereed":"nonPeerReviewed"},{"type":"Conference object","urls":["https://avesis.deu.edu.tr/publication/details/29a63cf4-db67-4618-b1b0-678b71f402f0/oai"],"publicationDate":"2018-10-23","refereed":"nonPeerReviewed"},{"pids":[{"scheme":"handle","value":"11468/17716"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12737"}],"type":"Article","urls":["https://hdl.handle.net/11468/17716","https://doi.org/10.1111/jvp.12737"],"publicationDate":"2024-04-24","refereed":"nonPeerReviewed"},{"pids":[{"scheme":"handle","value":"20.500.12395/38080"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12737"}],"type":"Article","urls":["https://hdl.handle.net/20.500.12395/38080","https://doi.org/10.1111/jvp.12737"],"publicationDate":"2019-01-01","refereed":"nonPeerReviewed"}],"isGreen":true,"isInDiamondJournal":false} | |
| local.import.source | OpenAire | |
| local.indexed.at | WOS | |
| local.indexed.at | Scopus | |
| local.indexed.at | PubMed |
